Pathological expression of human ErbB-2 protein, also known as HER-2, is common in many types of cancer. ErbB-2 is a member of the EGF receptor tyrosine kinase family and has been rigorously studied as a signaling molecule on the cell membrane. Here, we report that ErbB-2 is also expressed in the nucleus in cultured cells as well as primary tumor tissues. Nuclear ErbB-2 was found to associate with multiple genomic targets in vivo, including the cyclooxygenase enzyme COX-2 gene promoter. ErbB-2 forms a complex at a specific nucleotide sequence of the COX-2 promoter and is able to stimulate its transcription. This study demonstrates the presence of ErbB-2 in the nucleus and identifies the function of ErbB-2 as a transcriptional regulator.
.
pressed a basal level of ErbB-2 (data not shown). Consistent with these results, ErbB-2 protein was detected in the nuclear Indeed, a recent large-scale clinical investigation involving 1576 patients with breast cancer revealed a significant correlation fraction of ErbB-2-expressing breast cancer cells by cellular fractionation and immunoblot analysis ( Figure 1H ). It is known between COX-2 and ErbB-2 expression in primary tumors (Ristimä ki et al., 2002) .
that tyrosine kinase activity of tyrosine kinase receptors is required for endocytosis, so we also examined nuclear expression Although it is commonly accepted that tyrosine kinase receptors such as the EGFR family proteins function as signaling of ErbB-2 in the presence of a ErbB-2-specific kinase inhibitor AG825 (Levitzki and Gazit, 1995) . The result indicated that the initiators on the cell membrane, there is accumulating evidence indicating nuclear expression of growth factors and their recepkinase inhibitor blocked nuclear expression of ErbB-2, suggesting that tyrosine kinase activity is required for nuclear transtors (Carpenter, 2003; Clevenger, 2003; Keresztes and Boonstra, 1999; Wells and Marti, 2002) . In addition to the EGFR family location of ErbB-2 ( Figure 1I ). In addition to cell lines, we also detected nuclear ErbB-2 in multiple types of primary human proteins ErbB-1, ErbB-3, and ErbB-4 (Lin et al., 2001; Ni et al., 2001; Offterdinger et al., 2002; Xie and Hung, 1994) , nuclear tumor tissue by immunohistochemical staining ( Figure 6 ). Thus, the ErbB-2 thought to be a cell surface membrane receptor translocation of other tyrosine kinase receptors, including vascular endothelial growth factor (VEGF) receptor (Feng et al., can be detected in the nucleus by four different approaches, including fluorescence microscopy, electron microscopy, bio-1999), nerve growth factor (NGF) receptor (Rakowicz-Szulczynska et al., 1988) , and fibroblast growth factor (FGF) receptor chemical fractionation, and immunohistochemistry in tumor tissues ( Figure 6 ). These results also suggest that nuclear ErbB-2 (Maher, 1996; Reilly and Maher, 2001) , have been reported. However, the potential nuclear functions of these receptors/ is an intact molecule, as it can be detected by antibodies against both N-and C-terminal epitopes of ErbB-2 protein and the size ligands remain elusive due to the fact that a systemic approach to identify their nuclear targets has not been established. To of nuclear ErbB-2 is the same as that of cytoplasmic ErbB-2. this regard, it is known that the carboxy-terminal acidic regions of EGFR and ErbB-4 contain an intrinsic transactivation function Binding of nuclear ErbB-2 to a specific DNA sequence of the COX-2 promoter and are able to transactivate a luciferase-based report system (Lin et al., 2001; Ni et al., 2001) . Indeed, we previously demonTo elucidate the function of nuclear ErbB-2, we explored the potential role of ErbB-2 as a gene regulator by investigating strated that the nuclear EGFR functions as a transcription factor to stimulate cyclin D1 expression (Lin et al., 2001) . Like EGFR the genomic targets associated with ErbB-2 using chromatin immunoprecipitation (ChIP). DNA fragments associated with and ErbB-4, the carboxyl terminus of ErbB-2 is also highly acidic, and this feature is conserved across different species, ErbB-2 were processed, cloned, and identified by sequencing, as depicted in Figure 2A . The promoter regions or introns identiincluding human, mouse, and rat (Xie and Hung, 1994 ).
In the current study, we provide evidence for nuclear expresfied by these clones were further verified by ChIP. Using this protocol, the genomic sequences of PRPK (Abe et al., 2001 ), sion and function for human ErbB-2 protein and identify important genomic targets of ErbB-2 using a strategy combining chroma- MMP-16 (Will and Hinzmann, 1995) , DDX-10 (Savitsky et al., 1996) , and COX-2 (Jones et al., 1993 ) associated with ErbB-2 tin immunoprecipitation, molecular cloning, and bioinformatic analysis. We demonstrate that nuclear ErbB-2 associates with were identified (Supplemental Figure S2A) . We chose to analyze the interaction between ErbB-2 and the COX-2 promoter in a specific sequence in the COX-2 promoter and upregulates expression of the COX-2 gene.
detail because overexpression of both ErbB-2 and COX-2 has been implicated in tumorigenesis of many human cancer types (Howe et al., 2001; Yarden and Sliwkowski, 2001 ). The cloned Results DNA fragment, which we named HER-2-associated sequence (HAS), is located 1750 nucleotides upstream from the transcripNuclear localization of ErbB-2 protein We detected nuclear ErbB-2 in ErbB-2-expressing human breast tional start site in this gene ( Figure 2B ). By using primers flanking the HAS, we detected association of ErbB-2 with the COX-2 cancer cell lines using different monoclonal antibodies against the amino (N) and the carboxyl (C) terminus of ErbB-2. In addition promoter in multiple breast cancer cell lines, including SK-BR-3, BT474 ( Figure 2C ), and MCF-7/HER ( Figure 2D ), as well as in to staining of the plasma membrane and perinuclear cytoplasm, both antibodies clearly showed punctate ErbB-2 expression in the ovarian cancer cell line SK-OV-3 ( Figure 2C ). In a parallel ChIP experiment to test the specificity of chromatin association the nucleus (the nuclear green spots marked by white arrows in Figures 1B and 1D-1F ). To rule out the possibility that the ( Figure 2D ), estrogen receptor was recruited to the pS2 promoter, a documented target of estrogen receptor (Berry et al., nuclear ErbB-2 was contaminated from the endoplasmic reticulum (ER), we stained cells with antibodies against the ER mark-1989), but not the HAS of COX-2 promoter. Conversely, ErbB-2 did not associate with the pS2 promoter or a distant genomic ers calreticulin ( Figures 1C, 1E , and 1F) and calnexin (data not shown). Whereas the perinuclear ErbB-2 mainly colocalized with sequence upstream from the COX-2 promoter. The same ErbB-2-DNA complex could be detected using ErbB-2 antibodies ER markers, the nuclear ErbB-2 did not ( Figures 1B, 1C, 1E , and 1F). Consistantly, when ErbB-2 expression was stably reagainst different epitopes (data not shown). A quantitative ChIP assay using real-time PCR further validated the recruitment of constituted in the MCF-7/HER cells, nuclear immunoreactivity of ErbB-2 was also detected (see Supplemental Figure S1 at ErbB-2 in the COX-2 promoter ( Figure 2E ). Significant ErbB-2 recruitment to the COX-2 promoter was detected in MCF-7 http://www.cancercell.org/cgi/content/full/6/3/251/DC1). Confirming this phenomenon, nuclear expression of ErbB-2 in the stable clones expressing ectopic ErbB-2 but not the MCF-7 parental cells, indicating that COX-2 occupancy was indeed MCF-7/HER cells was also demonstrated by electron microscopy ( Figure 1G ). Using this method, only minimal nuclear ErbB-2 dependent ( Figures 2F and 2G ). In addition, radiolabeled HAS oligonucleotide formed a specific complex with nuclear ErbB-2 could be detected in the parental MCF-7 cells that ex- , and the perinuclear ErbB-2 colocalized with calreticulin is shown in yellow (E, primarily in the perinuclear region). The staining was visualized by immunofluorescence microscopy with a deconvolution program. G: Detection of nuclear ErbB-2 by transmission electron microscopy (TEM). MCF-7/HER cells were processed for immuno-EM, sectioned, and labeled using monoclonal antibody to the N terminus of ErbB-2 (upper) or mouse IgG (lower) followed by anti-mouse antibody conjugated with 15 nm gold. Scale bar equals 200 nm. Cy, cytoplasm; Nu, nucleus; NE, nuclear envelope. H: The nuclear (Nuc) and cytoplasmic (Cyt) fractions of two cell lines (SK-BR-3 and MCF-7/HER cells) were subjected to immunoblot analysis. ␣-tubulin and poly(ADP-ribose) polymerase (PARP) were used as the cytoplasmic and nuclear markers, respectively. I: MCF-7/HER cells were treated with the ErbB-2-specific inhibitor AG825 (80 M) for 6 hr. Cytoplasmic (Cyt) and nuclear (Nuc) fractions were then prepared from the cells, and the expression of ErbB-2, tubulin, and PARP was analyzed by Western blotting.
ErbB-2, which was abolished by cold HAS or anti-ErbB-2 anticancers by inducing ErbB-2 internalization and subsequent degbodies but not by the consensus binding sequence of the tranradation (Klapper et al., 2000) . Consistently, our results showed scription factor AP2 or Sp1, an antibody against CD44, or normal that Herceptin treatment triggered ErbB-2 protein depletion and mouse IgG ( Figure 2H ). The ErbB-2 antibodies had no effect on mitigated the association between nuclear ErbB-2 and the the DNA binding activity of other transcription factors (data not COX-2 promoter ( Figure 3A ). shown). These results demonstrate that nuclear ErbB-2 associAs mentioned above ( Figure 1I ), the intrinsic tyrosine kinase ates with a specific genomic DNA sequence in the COX-2 proactivity of ErbB-2 is critical for its nuclear expression. Consismoter and that the ChIP cloning strategy can be used to identify tently, the wild-type ErbB-2 targeted the COX-2 promoter more target DNA sequences for nuclear receptor tyrosine kinases.
efficiently than did the kinase-deficient (kd) mutant, as demonstrated by stable transfectants established in the MCF-7 cell line ( Figure 3B ). Similar results were obtained using transient Functional ErbB-2 is required for formation transfection, in which the wild-type ErbB-2 also bound DNA of ErbB-2-COX-2 promoter complex more efficiently than the kd mutant (Supplemental Figure S3A ). It is known that ErbB-2 can be downregulated by Herceptin, which has been used in clinic to target ErbB-2-overexpressing
In addition, treating cells with the ErbB-2-specific tyrosine ki- Nuclei from the fixed ErbB-2-expressing breast cancer cells BT-474 were sonicated to fragment the genomic DNA. The ErbB-2-DNA complexes were next immunoprecipitated by an anti-ErbB-2 antibody. Copurified DNA fragments were cloned and the DNA was identified by sequencing. Genomic locations of the identified DNA sequences were determined by querying the GenBank.
B:
The sequence in the COX-2 promoter associated with ErbB-2 (boxed sequence). The nucleotide sequence required for ErbB-2 association is in red (see Figure 4 for details). The PCR primers for ChIP analysis are shown by small arrows with the coordinates indicated. C: ErbB-2-COX-2 association was confirmed in breast (SK-BR-3, BT474) and ovarian (SK-OV-3) cancer cell lines. ChIP was performed using either monoclonal anti-ErbB-2 antibody or IgG as the negative control. The target DNA was amplified by PCR using flanking primers as diagrammed in B. D: The pS2 promoter and the distal upstream region of the COX-2 promoter (Upstream) were examined by ChIP for the occupancy of ErbB-2 and estrogen receptor (ER) using anti-ErbB-2, anti-ER, or IgG antibody. E: Quantitative real-time PCR was used to verify the ChIP result obtained by conventional PCR as shown in the inset. F: Immunoblotting analysis was performed to verify the expression and phosphorylation of ErbB-2 in freshly established MCF-7 cell lines with (ErbB2) or without (Vector) ectopic ErbB-2 expression. G: ChIP analysis using anti-ErbB-2 antibody on the same MCF-7 derivatives characterized in F. Either the COX-2 promoter (COX2) or the upstream region of the COX-2 promoter (Upstream) was tested as described in C and D. The input was also amplified using the upstream primers as a positive control (Input). H: The radiolabeled HAS oligonucleotide (the boxed sequence in Figure 2B ) was used as the probe for electrophoretic mobility shift assay (EMSA). Lanes 1-4, the labeled probe was incubated with no antibody (lane 1) or with antibodies against ErbB-2 (lane 2), CD44 (lane 3), or IgG (lane 4). Lanes 5-8, competition assay using the cold oligonucleotides as indicated. Lanes 9-11, the binding reactions containing nuclear extracts and the labeled probe was challenged by adding different antibodies. The arrow indicates the ErbB-2/oligonucleotide complex. The stars indicate the disappeared ErbB-2-oligonucleotide complex competed by the cold HAS or the ErbB-2 antibodies. Relative intensities (ratio) of the indicated bands were shown at the bottom of the gel. NE, nuclear lysate.
nase inhibitor AG825, which prevented nuclear translocation of ErbB-2 inhibited its binding to the COX-2 promoter. These results together indicate that formation of the ErbB-2-COX-2 proErbB-2 ( Figure 1I ), consistently inhibited the association between ErbB-2 and the target COX-2 promoter (Supplemental moter complex depends on ErbB-2 expression and requires tyrosine kinase activity of ErbB-2. Figure S3B ). Thus, suppressing the tyrosine kinase activity of The MCF-7 stable cell line expressing wild-type ErbB-2 was treated with or without Herceptin (20 g/ml) for 84 hr, then processed for ChIP and Western blot analysis using ErbB-2 antibody. Tubulin expression is shown as loading control. B: Left, MCF-7 cell stable clones of wild-type ErbB-2 (wt), the kinase-deficient mutant of ErbB-2 (kd), or the vector (Vec) were tested for the occupancy of ErbB-2 on the COX-2 promoter by ChIP using ErbB-2 antibody; Right, immunoblot analysis for phosphorylated (ErbB2-P) and the total expression of ErbB-2 (ErbB2) and estrogen receptor (ER), which was used as an internal control.
Transactivation of the COX-2 promoter by ErbB-2
ErbB-2-mediated COX-2 transactivation, COX-2 full-length promoter containing the wild-type or the corresponding mutated through HAS DNA sequence To further investigate functionality of nuclear ErbB-2, we tested sequence at the HAS was cotransfected with ErbB-2 into MCF-7 cells. Expression of ErbB-2 was able to induce higher reporter whether ErbB-2 associated with transactivation activity. To this end, we found that the C-terminal domain (CD) of ErbB-2 congene expression from the wild-type than the HAS-mutated fulllength promoter ( Figure 5A ). Thus, the HAS on the COX-2 protained an intrinsic transactivation activity, as the Gal4-CD fusion protein induced a dramatic activation function toward a reporter moter plays a significant role in responding to the nuclear ErbB-2 transactivation function. However, the full-length promoter also gene under the control of a Gal4 binding sequence in the promoter ( Figure 4A ). To assess the transactivation potential of contains other transcription factor binding elements that can be modulated through the traditional signal transduction pathways. ErbB-2 in vivo, a 200 bp region containing the HAS was subcloned to control a luciferase reporter system. ErbB-2 cotransTo avoid the interference from the rest of the promoter sequence, the trimeric repeats of either the wild-type HAS or fection with the HAS-luciferase receptor induced the reporter activity ( Figure 4B ). We reasoned that, if the HAS mediates the corresponding mutant in the identified core sequence were subcloned into a plasmid to control a luciferase reporter. CoErbB-2-dependent gene activation, abolishing the ErbB-2-HAS interaction should therefore inhibit the activation. To test this transfection of the ErbB-2-expressing plasmid induced the reporter activity driven by the wild-type, but not the mutant, HAS hypothesis, we first determined whether the recruitment of ErbB-2 depends on specific nucleotide residues on the HAS.
( Figure 5B ). On the other hand, the HAS-mediated reporter activity responded only to the wild-type ErbB-2 but not to the mutant The nucleotides of the HAS were mutated in series by transversion-transition (A to C or T to G, for example) in 5-base windows.
ErbB-2, which can not translocate to the nucleus (Supplemental Figure S2C) . Thus, these results show that ErbB-2 formed a The resultant double-strand mutant oligonucleotides were then used to compete with the wild-type HAS in EMSA assays. The complex with the COX-2 promoter in the nucleus and transactivated the COX-2 gene promoter. Consistently, ectopic expresmutants lost their competitive activity, which would suggest that the mutated sequences are critical for ErbB-2 association.
sion of ErbB-2 enhanced the mRNA and protein expression from the endogenous COX-2 gene ( Figure 5C ). In addition to Thus, we identified a subsequence critical for ErbB-2 association, with region C being the most important, followed by the COX-2, functional verification of the PRPK promoter, which was also identified by ChIP cloning (Supplemental Figure S2A) , demflanking regions B and D ( Figure 4C ; Table 1 ). A more detailed permutation analysis in regions B and D demonstrated that the onstrated that ErbB-2 was able to transactivate the full-length wild-type promoter, but not the mutant promoter in which the TCAAATTTC sequence (residues marked in red in Figure 2B ) was required for ErbB-2 association. Mutations within this reErbB-2-associating DNA motif was mutated, in a kinase activitydependent manner (Supplemental Figure S2B ). This observation gion of the HAS abolished competivity of the oligonucleotides ( Figure 4D ). Further analysis by EMSA showed that the "core" further supports the role of ErbB-2 as a transactivator in the nucleus. oligonucleotide, which contains the TCAAATTTC sequence flanked by randomly chosen sequences (Table 1) , formed a specific complex with the nuclear ErbB-2 ( Figure 4E ). Formation Correlation of COX-2 expression with nuclear ErbB-2 and ErbB-2-COX-2 promoter of this complex was blocked by competition with the cold HAS, the core oligonucleotide or anti-ErbB-2 antibodies, but not the complex in human tumor tissues To explore the physiological function of ErbB-2 in the nuclei of AP2 binding sequence or the anti-CD44 control antibody. Consistently, biotinylated wild-type, but not the mutant, HAS oligohuman breast tumor cells, a cohort of 30 archived primary breast cancer tissues were stained by immunohistochemistry for ErbB-2 nucleotide was able to associate with ErbB-2 protein in an oligonucleotide pull-down assay ( Figure 4F) . and COX-2 expression ( Figure 6A ; Supplemental Figure S4A ). ErbB-2 nuclear expression closely correlated with total ErbB-2 To test whether the identified core sequence is critical for Figure 4 . The ErbB2-COX2 complex was associated with transactivation expression (p ϭ 0.008). While total ErbB-2 expression was assoother ErbB-2-negative tumor, which was included as a negative control. These results demonstrate ErbB-2 nuclear expression ciated with COX-2 expression (Pearson correlation coefficient r ϭ 0.399, p ϭ 0.029), nuclear expression of ErbB-2 was more and that the COX-2 gene is a target of the nuclear ErbB-2 in human primary breast tumors. In addition to breast cancer, significantly correlated with COX-2 expression (Pearson correlation coefficient r ϭ 0.582, p ϭ 0.001). The status of total and nuclear expression of ErbB-2 was also detected in other cancer types, including small bowel, esophagus, and kidney, sugnuclear ErbB-2 expression as well as COX-2 expression in the tumor tissues is summarized in Supplemental Figure S4B . To gesting that nuclear ErbB-2 may be a general phenomenon in multiple cancer types ( Figure 6C ). To further address whether test whether ErbB-2 can be recruited to the COX-2 promoter in primary tumor tissues, a cohort of fresh surgically excised the enhanced COX-2 expression by ErbB-2 is required for ErbB-2-mediated malignancy, we compared the effect of COX-2 inhitumors from different breast cancer patients were processed for ChIP analysis. As demonstrated by the representative result bition on the invasion activity between MCF-7 and its ErbB-2 transfectants. As mentioned earlier, the ErbB-2 transfectant exshown in Figure 6B , association of ErbB-2 with the COX-2 promoter was detected in a ErbB-2-positive tumor but not in anpressed higher level of COX-2 than the MCF-7 parental cells 
The corresponding COX-2 promoter sequence complexed with ErbB-2 (as the sequence boxed in Figure 2B ) is in capital letters. The mutated nucleotides are underlined. The identified essential residues for ErbB-2 complex formation are in italics. a The compatibility was defined empirically by the EMSA competition assay as shown in Figures 4C-4E , in which the particular cold oligonucleotide was scored "ϩ" if it was able to diminish the ErbB-2-HAS complex. Thus, the mutants B2/B3 and D/D4 defined, respectively, the 5Ј and 3Ј boundaries of the HAS sequence required for ErbB-2-HAS complex formation.
( Figure 5C ). Treatment by two classic COX-2-specific inhibitors Discussion in clinic, celecoxib (Celebrex) and rofecoxib (Vioxx) (Flower, 2003) , preferentially suppressed the invasion activity of the Nuclear expression of other human EGFR family proteins, ErbB-2-expressing cells ( Figure 6D to all EGFR family members. However, the EGFR family proteins line MDA-MB-435 and its ErbB-2 transfectant were tested (data appear to adopt different mechanisms for nuclear translocation. not shown). Thus, these results indicate that the ErbB-2-induced Although EGFR and ErbB-3 translocate to the nucleus in full COX-2 expression is critical for its malignancy.
length, ErbB-4 is first processed by membrane proteinases and the resulting intracellular fragment is then transported to the nucleus. In the case of ErbB-2, like EGFR and ErbB-3, the membrane form of the protein seems to be identical to its nuclear form, as judged by the different antibodies against epitopes at the amino-and carboxy-terminal regions in immunostaining, as well as the Western blot analysis that shows that the nuclear ErbB-2 migrates at the same position as does the total ErbB-2 (Figure 1 ; Supplemental Figure S1 ). These results indicate that ErbB-2 translocates to the nucleus in its full-length form. However, the possibility that the same receptor may use different mechanisms for nuclear translocation under different conditions should not be excluded. By using an approach combining molecular cloning and bioinformatic analysis, we demonstrate that the nuclear ErbB-2 targets several gene promoters, including the COX-2 gene promoter, to mediate gene expression. The interaction between ErbB-2 nuclear expression. However, since ErbB-2 lacks any (mut) HAS was cotransfected with ErbB-2 cDNA or the vector control known structural signatures required for DNA association, it is (pcDNA3) into MCF-7 cells, and the relative luciferase reporter activity was measured.
likely that ErbB-2, and possibly other EGFR family members, B: A luciferase reporter controlled by the wild-type (wt) or mutant (Mut) does not directly interact with genomic DNA. Rather, they may HAS as trimeric repeat was cotransfected into MCF-7 cells with an ErbB-2-associate with other DNA binding nuclear factors. In this regard, expressing plasmid or the vector pcDNA3, and the relative luciferase activity it has been shown previously that Schwannoma-derived growth was determined. C: RNA and protein expression of the COX-2 gene was determined for the factor (SDGF), a rodent ligand for EGFR, can directly bind to freshly established stable clone of the MCF-7 cells expressing ErbB-2 (HER)
AT-rich DNA sequences (Kimura, 1993) , which are similar to the or the vector control (Vec). RT-PCR, reverse transcriptase-polymerase chain sequences associated with nuclear EGFR (Lin et al., 2001) . In reaction; WB, Western blotting; n.s., nonspecific bands. The same cell lines were also used in a functional assay as described in Figure 6D .
addition, it is worth mentioning that the association of EGFR Figure 6 . ErbB-2 associated with COX-2 expression in primary human breast tumors A: 30 archived primary breast cancer tissues were analyzed by immunohistochemistry staining using antibodies against ErbB-2 and COX-2 as described in the Experimental Procedures. In addition to membrane-cytoplasm localization, ErbB-2 expression was also observed in the nucleus in certain areas (examples indicated by arrows). Statistic analysis confirmed that the nuclear expression of ErbB-2 is significantly correlated with COX-2 expression in the neighboring tumor tissue sections (see text). B: ChIP analysis was done for fresh surgically excised tumor samples from breast cancer patients. The DNA-protein complex was pulled down by an antiErbB-2 monoclonal antibody (Ab-5, Oncogene) or IgG, and the resulting DNA was PCR amplified by the primers on the COX-2 promoter as described in Figure 2 . Representative results are shown. C: Tissue sections derived from different tumor types, including small bowel, breast, esophagus, kidney, and oral tumors were stained with anti-ErbB-2 antibody as described in the Experimental Procedures. White arrows indicate examples of nuclear ErbB-2 expression. Bottom: the oral cancer tissue, although it expressed high level of ErbB-2 in the cytoplasm, had a lack of nuclear ErbB-2 expression. Another breast cancer tumor tissue was also shown at the bottom as an ErbB-2-negative example. D: COX-2 inhibition suppressed invasion activity in ErbB2-expressing breast cancer cells. The enhanced invasion activity of ErbB-2-expressing cancer cells (HER) was blocked by specific COX-2 inhibitor, celecoxib (50 M) and rofecoxib (100 M), when compared with the parental cells (MCF-7). The invasion chambers were incubated for 45 hr and the filter was fixed and then stained with DAPI. The number of invaded cells was determined by counting multiple areas (Ͼ3) under a fluorescence microscope at 100ϫ amplification power.
with a histone 3 isoform has been reported recently (Blagoev an important issue in cancer chemoprevention and therapy (Howe et al., 2001; Turini and DuBois, 2002) . In breast cancer, et al., 2003) . One can therefore envision that the tyrosine kinase receptors in the nucleus may have a more global genomic funchigh level of COX-2 expression has a tight correlation with ErbB-2 expression (Ristimä ki et al., 2002; Subbaramaiah et al., tion. In line with this prospect, nuclear ErbB-2 forms punctate subnuclear structure, which partially overlaps with the promy-2002), and the current study described here provides an unexpected mechanism in which the nuclear ErbB-2 protein activates elocytic leukaemia (PML) protein (Supplemental Figure S6) . PML, either in the form of matrix-associated discrete nuclear the COX-2 promoter in breast cancer tissues as well as in cultured cancer cells. Besides the tumor types mentioned above, speckles or in the form of soluble nonmatrix distribution, has been linked to a wide range of nuclear functions including tranwe analyzed a gastric cancer cDNA microarray data set deposited online by others and found that significant correlation bescriptional regulation (Zhong et al., 2000) . Whether and how the nuclear tyrosine kinase receptors are functionally involved in tween ErbB-2 and COX-2 expression can also be extended to gastric cancer (Supplemental Figure S7 ; Chen et al., 2003) . chromatic modulating and gene regulation becomes a fundamental biological question which should be further explored.
Interestingly, the analysis showed that the ErbB-2-COX-2 correlation becomes more significant in metastatic tumor tissues, The cyclooxygenase enzyme COX-2 is one of the major contributors in tumor development. Increased expression of suggesting that the interaction between the ErbB-2 and COX-2 pathways is correlated with the advance of tumor development occurs in multiple cells within the tumor microenvironment and has an impact on angiogenesis, invasiveness, and antiapoptotic in certain cancer types. It remains to be tested whether nuclear ErbB-2 preferentially occurs in metastatic tumor tissues in gaspotential (Gately, 2000; Takahashi et al., 1999; Tsujii et al., 1997 gene, were verified by ChIP analysis (Supplemental Figure S8A ).
After three washes with PBS, the FITC-conjugated secondary antibody was then applied for 45 min at room temperature. The nucleus was stained with
ErbB-2 expression resulted in transactivation of the FANCC DAPI (fluorescence) or TOPRO 3 (confocal) before mounting. For immunopromoter (Supplemental Figure S8B) . The FANCC protein is fluorescence microscopy, the images were captured with a Zeiss AxioPlan2 critically involved in the repair of DNA damage generated from fluorescence microscope with a digital camera. The confocal microscopy oxidative stress, and expression of FANCC prevents apoptosis was performed by a Zeiss CLM510 laser microscope. (Ahmad et al., 2002; Pagano and Youssoufian, 2003 to identify their nuclear targets. In the current study, we develeluted twice with 30 l 0.1 M citrate (pH 3.0). Then, 240 l extraction buffer oped a cloning strategy involving ChIP to identify specific DNA (0.1% SDS, 50 mM NaHCO 3 , 5 l of 10 mg/ml RNase, 18 l of 5 M NaCl) was added to the pooled elutent and incubated at 65ЊC overnight. The sequences as nuclear targets for the nuclear ErbB-2 in vivo.
reverted DNA was purified with a miniprep spin column (Qiagen) and then
The strategy used in the current study is simpler and more eluted in 50 l of 10 mM Tris-HCl (pH 8.0). The COX-2 promoter region was physiologically relevant than the casting method that we pre- of the functions of nuclear tyrosine kinase receptors that have
For real-time PCR, the program was 95ЊC for 3.5 min, followed by 40 cycles been overlooked for decades.
of 95ЊC for 15 s and 50ЊC for 30 s. The real-time PCR was performed using the iCycler system (Bio-Rad).
Experimental procedures

Cloning of the ChIP fragments Cell culture, antibodies, and tissue slide
The immunoprecipitated DNA was processed and cloned as described preAll cell lines were maintained in DMEM/F12 with 10% fetal bovine serum.
viously (Weinmann et al., 2001) . Briefly, the DNA isolated from ChIP was The following antibodies were purchased: ErbB-2 (Oncogene, San Diego, heated at 68ЊC for 5 min then cooled to 37ЊC. One to two units of T4 DNA CA; DAKO); CD44, calnexin, and PML (Santa Cruz); COX-2 (Oxford Biochempolymerase was added to the DNA and reaction mix containing the repair ical); phosphotyrosine (Upstate); PARP (BD Biosciences); and ␣-tubulin buffer (18 mM ammonium sulfate, 66 mM Tris [pH 8.0], 6.6 mM MgCl 2 , 50 (Sigma). The tissue slide including multiple types of human tumors was mM ␤-mercaptoethanol, and 0.5 mM of each nucleotide) and incubated at purchased from Imgenex.
37ЊC for 15 min. The reaction was terminated by 1 l of 0.5 M EDTA for a 50 l reaction mix. The processed DNA was cloned into pBluescript vector, Plasmids and reporter assay which was linearized by Eco321 (Fermentas) and dephosphorylated by calf The cytoplasmic region (amino acids 727-1234), kinase domain (amino acids intestine phosphatase. 727-986), and C-terminal region (amino acids 987-1234) of ErbB-2 (Yamamoto et al., 1986) were amplified by PCR and cloned in-frame into the Electrophoretic mobility shift assay pSG424 vector. The constructs were cotransfected with the pG5-TK-Luc Double-stranded oligonucleotides (Genosys/Sigma-Aldrich) were end lareporter plasmid to assess the transactivation activity of the fusion proteins.
beled by ␣-32 P using T4 polynucleotide kinase (Promega) and then purified The ErbB-2-associated DNA fragments were cloned into the pGL3-promoter by phenol:chloroform:isoamyl ethanol (25:24:1) extraction. 10 g of nuclear vector and transfected along with the pRL-TK reporter plasmid (Promega).
extracts were incubated with 5 ng radiolabeled probes in 10 mM Tris-HCl Luciferase assays were carried out using the Dual-Luciferase assay kit (Pro-(pH 7.5), 50 mM NaCl, 1 mM MgCl 2 , 4% glycerol, 0.5 mM EDTA, 0.5 mM mega). The pG5-TK-Luc and pSG424 plasmids were generous gifts from DDT, and 1.25 g poly(dI-dC).poly(dI-dC) (Amershan Pharmacia Biotech). Dr. Marilyn Szentirmay. The wild-type full-length COX-2 promoter-luciferase After 15 min at room temperature, the reaction was terminated by adding 10ϫ construct was provided by Dr. Miguel Angel Iñ iguez.
gel loading buffer (250 mM Tris-HCl [pH 7.5], 40% glycerol) and separated by electrophoresis at 4ЊC in a 5% nondenaturing polyacrylamide gel (acrylCellular fractionation amide:bis-acrylamide, 50:1) containing 0.5ϫ TBE and 2.5% glycerol. In the The cytoplasmic and nuclear fractions were prepared as described (Maher, competition experiments, nuclear extracts were preincubated with a 200-fold 1996), except that the nuclei were lysed in RIPA buffer (150 mM NaCl, 20 excess of a cold competitive oligonucleotide for 15 min before 32 P-labeled mM Na 2 HPO 4 , 1% TritonX-100, 100 mM NaF, 2 mM Na 3 VO 4 , 5 mM PMSF, probes were added. To verify the involvement of ErbB-2 in the complex, 0.5-2.0 2 g/ml aprotinin, 2 g/ml leupeptin, and 0.5 mg/ml benzamidine) by sonicag of antibodies against ErbB-2 (a cocktail of Ab-3 and Ab-5 from Oncogene tion (Sonics Vibra Cell, amplitude 20). The fractionation efficiency was asand Ab-11 from NeoMarker) or equal amount of anti-CD44 antibody (Santa Cruz) or mouse IgG was added to the mixture containing the nuclear extracts sessed by antibodies against ␣-tubulin and PARP. and radiolabeled probes and incubated at room temperature or on ice for
The cell number on the filter was scored under a fluorescence microscope with the aid of an image processing software (alphaEaseFC; ␣ Innotech). an additional 10 min.
